Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IICompletedJun 11, 2025Fluoxetine TabletsCGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc. · D-0456-2025Class IICompletedJun 11, 2025Fluoxetine TabletsCGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc. · D-0455-2025Class IIOngoingJun 11, 2025Indomethacin Extended-Release CapsulescGMP deviationsAmerisource Health Services LLC · D-0454-2025Class IOngoingJun 4, 2025ENDURANCE BOOST WITH HORNY GOAT WEEDMarketed without approved NDA/ANDA: The product has been found to be tainted with Sildenafil and Propoxyphenylsildenafil (a sildenafil analogue).EnShiShiXiangNiShangMaoYouXianGongSi · D-0453-2025Class IIOngoingJun 4, 2025TheophyllineOOS results reported for the Dissolution (by UV) test.Glenmark Pharmaceuticals Inc., USA · D-0452-2025Class IIOngoingJun 4, 2025Carvedilol Tablets USP 25 mgCGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limitGlenmark Pharmaceuticals Inc., USA · D-0451-2025Class IIOngoingJun 4, 2025Carvedilol Tablets USP 12.5 mgCGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limitGlenmark Pharmaceuticals Inc., USA · D-0450-2025Class IIOngoingJun 4, 2025Carvedilol Tablets USP 6.25 mgCGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limitGlenmark Pharmaceuticals Inc., USA · D-0449-2025Class IIOngoingJun 4, 2025Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottleCGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limitGlenmark Pharmaceuticals Inc., USA · D-0448-2025Class IIOngoingJun 4, 2025Bromfenac Ophthalmic Solution 0.09%Failed Impurities/Degradation SpecificationsAlembic Pharmaceuticals Limited · D-0447-2025Class IIOngoingMay 28, 2025Phentermine Hydrochloride CapsulescGMP deviationsKVK Tech, Inc. · D-0446-2025Class IIOngoingMay 28, 2025Indomethacin Extended-Release Capsules USPcGMP deviationsKVK Tech, Inc. · D-0445-2025Class IIOngoingMay 28, 2025AirsupraDefective delivery systemAsttraZeneca Pharmaceuticals LP · D-0444-2025Class IIOngoingMay 28, 2025Esomeprazole Magnesium for Delayed-Release Oral SuspensionFailed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing...Zydus Pharmaceuticals (USA) Inc · D-0443-2025Class IIOngoingMay 28, 2025Esomeprazole Magnesium for Delayed-Release Oral SuspensionFailed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing...Zydus Pharmaceuticals (USA) Inc · D-0442-2025Class IIOngoingMay 28, 2025BD ChloraPrep ClearLack of Assurance of Sterility: The affected product may exhibit an open seal on the packaging of the applicator.CareFusion 213, LLC · D-0441-2025Class IITerminatedMay 28, 2025Nature MintCGMP DeviationsKenil Healthcare Private Limited · D-0440-2025Class IITerminatedMay 28, 2025Nature Mint Anticavity Fluoride ToothpasteCGMP DeviationsKenil Healthcare Private Limited · D-0439-2025Class IITerminatedMay 28, 2025Nature Mint Anticavity Fluoride ToothpasteCGMP DeviationsKenil Healthcare Private Limited · D-0438-2025Class IITerminatedMay 28, 2025Nature MintCGMP DeviationsKenil Healthcare Private Limited · D-0437-2025Class IITerminatedMay 28, 2025Nature MintCGMP DeviationsKenil Healthcare Private Limited · D-0436-2025Class IITerminatedMay 28, 2025Nature MintCGMP DeviationsKenil Healthcare Private Limited · D-0435-2025Class IITerminatedMay 28, 2025Maximum SecurityCGMP DeviationsKenil Healthcare Private Limited · D-0434-2025Class IITerminatedMay 28, 2025Maximum SecurityCGMP DeviationsKenil Healthcare Private Limited · D-0433-2025Class IITerminatedMay 28, 2025Maximum SecurityCGMP DeviationsKenil Healthcare Private Limited · D-0432-2025Class IITerminatedMay 28, 2025Maximum Security Anticavity Gel ToothpasteCGMP DeviationsKenil Healthcare Private Limited · D-0431-2025Class IITerminatedMay 28, 2025Cinnafresh anticavity gel toothpasteCGMP DeviationsKenil Healthcare Private Limited · D-0430-2025Class IITerminatedMay 28, 2025Rapidol, Triple Antibiotic First Aid OintmentCGMP DeviationsKenil Healthcare Private Limited · D-0429-2025Class IITerminatedMay 28, 2025Rapidol Maximum StrengthCGMP DeviationsKenil Healthcare Private Limited · D-0428-2025Class IITerminatedMay 28, 2025Optim V, Anti-Itch CreamCGMP DeviationsKenil Healthcare Private Limited · D-0427-2025Class IITerminatedMay 28, 2025KOFAL, AthletesCGMP DeviationsKenil Healthcare Private Limited · D-0426-2025Class IITerminatedMay 28, 2025KOFAL OriginalCGMP DeviationsKenil Healthcare Private Limited · D-0425-2025Class IITerminatedMay 28, 2025KingskinCGMP DeviationsKenil Healthcare Private Limited · D-0424-2025Class IITerminatedMay 28, 2025CURA HONGOSCGMP DeviationsKenil Healthcare Private Limited · D-0423-2025Class IITerminatedMay 28, 2025CURA HONGOSCGMP DeviationsKenil Healthcare Private Limited · D-0422-2025Class IITerminatedMay 28, 2025Artridon GlucosamineCGMP DeviationsKenil Healthcare Private Limited · D-0421-2025Class IIOngoingMay 21, 2025Testosterone Cypionate InjectionLack of Assurance of SterilityEmpower Clinic Services, LLC dba Empower Pharmacy · D-0420-2025Class IIOngoingMay 21, 2025La Roche-Posay Laboratoire Dermatologique Effaclar Duo Dual Action Acne TreatmentcGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution...L'Oreal USA · D-0419-2025Class IIOngoingMay 21, 2025La Roche-Posay Laboratoire Dermatologique Effaclar Dermatological Acne SystemcGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution...L'Oreal USA · D-0418-2025Class IIOngoingMay 21, 2025La Roche-Posay Laboratoire Dermatologique Effaclar Duo Dual Action Acne TreatmentChemical Contamination: This recall has been initiated due to detected trace levels of benzene.L'Oreal USA · D-0417-2025